The contribution of endothelial cell P-selectin to the microvascular flow of mouse sickle erythrocytes in vivo

Blood

Volumn 104, Issue 10, 2004, Pages 3378-3385

  Embury, Stephen H ^a   Matsui, Neil M ^b   Ramanujam, Sahana ^b   Mayadas, Tanya N ^b   Noguchi, Constance T ^b   Diwan, Bhalchandra A ^b   Mohandas, Narla ^b   Cheung, Anthony T W ^b  

^a SAN FRANCISCO GENERAL HOSPITAL   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

HEPARIN; MONOCLONAL ANTIBODY; PADGEM PROTEIN; PROTEIN PROTEINASE ACTIVATED RECEPTOR 1 AGONIST; PROTEINASE ACTIVATED RECEPTOR 1; THROMBIN RECEPTOR ACTIVATING PEPTIDE; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; BLOOD FLOW; BLOOD RHEOLOGY; BLOOD VESSEL OCCLUSION; CELL ACTIVATION; CONTROLLED STUDY; ENDOTHELIUM CELL; ERYTHROCYTE ADHESIVENESS; FLOW RATE; IN VITRO STUDY; IN VIVO STUDY; KNOCKOUT MOUSE; LEUKOCYTE ADHERENCE; MICROCIRCULATION; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; SICKLE CELL; THROMBOCYTE ACTIVATION;

EID: 8644256005     PISSN: 00064971     EISSN: None     Source Type: Journal    
DOI: 10.1182/blood-2004-02-0713     Document Type: Article

References (78)

1. Embury SH, Hebbel RP, Mohandas N, Steinberg MH. Sickle Cell Anemia: Basic Principles and Clinical Practice. New York, NY: Raven Press; 1994.
2. Chien S. Rheology of sickle cells and erythrocyte content. Blood Cells. 1977;3:283-303.
3. Eaton WA, Hofrichter J. Sickle cell hemoglobin polymerization. Adv Protein Chem. 1990;40:63-279.
4. Embury SH, Hebbel RP, Mohandas N, Steinberg MH. Pathogenesis of vasoocclusion. In: Embury SH, Hebbel RP, Mohandas N, Steinberg MH, eds. Sickle Cell Disease: Basic Principles and Clinical Practice. New York, NY: Raven Press; 1994:311-326.
5. Kaut DK, Fabry ME, Nagel RL. Microvascular sites and characteristics of sickle cell adhesion to vascular endothelium in shear flow conditions: pathophysiological implications. Proc Natl Acad Sci U S A. 1989;86:3356-3360.
6. Embury SH. The not-so-simple process of sickle cell vasoocclusion. Microcirculation. 2004;11:101-113.
7. Harlan JM. Introduction: anti-adhesion therapy in sickle cell disease. Blood. 2000;95:365-367.
8. Hebbel RP. Clinical implications of basic research: blockade of adhesion of sickle cells to endothelium by monoclonal antibodies. N Engl J Med. 2000;342:1910-1912.
9. Solovey A, Lin Y, Browne P, Choong S, Wayner E, Hebbel RP. Circulating activated endothelial cells in sickle cell anemia. N Engl J Med. 1997;337:1584-1589.
10. Wood KC, Hebbel RP, Granger DN. Endothelial cell P-selectin mediates a proinflammatory and prothrombogenlc phenotype in cerebral venules of sickle cell transgenic mice. Am J Physiol Heart Circ Physiol. 2004;286:H1608-H1614.
11. Wood K, Russell J, Hebbel RP, Granger DN. Differential expression of E- and P-selectin in the microvasculature of sickle cell transgenic mice. Microcirculation. 2004;11:377-385.
12. Ley K. Molecular mechanisms of leukocyte recruitment in the inflammatory process. Cardiovasc Res. 1996;32:733-742.
13. Francis RB. Elevated fibrin D-dimer fragment in sickle cell anemia: evidence for activation of coagulation during the steady state as well as in painful crisis. Haemostasis. 1989;19:105-111.
14. Peters M, Plaat BE, ten Cate H, Wolters HJ, Weening RS, Brandjes DP. Enhanced thrombin generation in children with sickle cell disease. Thromb Haemost. 1994;71:169-172.
15. Matsui NM, Borsig L, Rosen SD, Yaghmai M, Varki A, Embury SH. P-selectin mediates the adhesion of sickle erythrocytes to the endothelium. Blood. 2001;98:1955-1962.
16. Matsui NM, Varki A, Embury SH. Heparin inhibits the flow adhesion of sickle red blood cells to P-selectin. Blood. 2002;100:3790-3796.
17. Lipowsky HH, Sheikh NU. Katz DM. Intravital microscopy of capillary microdynamics in sickle cell disease. J Clin Invest. 1987;80:117-127.
18. Cheung AT, Chen PC, Larkin EC, et al. Microvascular abnormalities in sickle cell disease: a computer-assisted intravital microscopy study. Blood. 2002;99:3999-4005.
19. Kaul DK, Fabry ME, Costantini F, Rubin EM, Nagel RL. In vivo demonstration of red cell-endothelial interaction, sickling and altered microvascular response to oxygen in the sickle transgenic mouse. J Clin Invest. 1995;96:2845-2853.
20. Embury SH, Mohandas N, Paszty C, Cooper P, Cheung ATW. In vivo blood flow abnormalities in the transgenic knockout sickle cell mouse. J Clin Invest. 1999;103:915-920.
21. Knisely MH, Bloch EH, Eliot TS, Warner L. Sludged blood. Science. 1947;106:431-440.
22. Fink AI, Funahashi T, Robinson M, Watson RJ. Conjunctival blood flow in sickle-cell disease. Arch Ophthalmol. 1961;66:824-829.
23. Rodgers GP, Schechter AN, Noguchi CT, Klein HG, Nienhuis AW, Bonner RF. Periodic microcirculatory flow in patients with sickle-cell disease. N Engl J Med. 1984;311:1534-1538.
24. French JA, Kenny D, Scott JP, et al. Mechanisms of stroke in sickle cell disease: sickle erythrocytes decrease cerebral blood flow in rats after nitric oxide synthase inhibition. Blood. 1997;89:4591-4459.
25. Lutty GA, Taomoto M, Cao J, et al. Inhibition of TNF-alpha-induced sickle RBC retention in retina by a VLA-4 antagonist. Invest Ophthalmol Vis Sci. 2001;42:1349-1355.
26. Lutty GA, Otsuji T, Taomoto M, et al. Mechanisms for sickle red blood cell retention in choroid. Curr Eye Res. 2002;25:163-171.
27. Turhan A, Weiss LA, Mohandas N, Coller BS, Frenette PS. Primary role for adherent leukocytes in sickle cell vascular occlusion: a new paradigm. Proc Natl Acad Sci U S A. 2002;99:3047-3051.
28. Embury SH, Matsui NM. Thrombin, endothelial gap formation, and eryhrocyte adhesion. In: Weir EK, Reeve HL, Reeves JT, eds. Interactions of Blood and the Pulmonary Circulation. Armonk, NY: Futura Publishing; 2002:35-68.
29. Paszty C, Brion CM, Manci E, et al. Transgenic knockout mice with exclusively human sickle hemoglobin and sickle cell disease. Science. 1997;278:876-878.
30. Coughlin SR. Thrombin signalling and protease-activated receptors. Nature. 2000;407:258-264.
31. Sarelius IH, Duling BR. Direct measurement of microvesset hematocrit, red cell flux, velocity, and transit time. Am J Physiol. 1982;243:H1018-H1026.
32. Mayadas TN, Johnson RC, Rayburn H, Hynes RO, Wagner DD. Leukocyte rolling and extravasation are severely compromised in P selectin-deficient mice. Cell. 1993;74:541-554.
33. Beutler E, Gelbart T. The mechanism of removal of leukocytes by cellulose columns. Blood Cells. 1986;12:57-64.
34. Mazo IB, Gutierrez-Ramos JC, Frenette PS, Hynes RO, Wagner DD, von Andrian UH. Hematopoietic progenitor cell rolling in bone marrow microvessels: parallel contributions by endothelial selectins and vascular cell adhesion molecule 1. J Exp Med. 1998;188:465-474.
35. Cheung ATW, Young LJT, Chen PCY, et al. Microcirculation and metastasis in a new mouse mammary tumor model system. Int J Oncol. 1997;11: 69-77.
36. Lipowsky HH, Usami S, Chien S. Human SS red cell rheologic behavior in the microcirculation of cremaster muscle. Blood Cells. 1982;8:113-126.
37. Chi JT, Chang HY, Haraldsen G, et al. Endothelial cell diversity revealed by global expression profiling. Proc Natl Acad Sci U S A. 2003;100:10623-10628.
38. Hattori R, Hamilton KK, Fugates RD, McEver RP, Sims PJ. Stimulated secretion of endothetial von Willebrand factor is accompanied by rapid redistribution to the cell surface of the intracellular granule membrane protein GMP-140. J Biol Chem. 1989;264:7768-7771.
39. Mazza JJ, Gatlin PF, Marx JJ Jr. Inhibition of platelet aggregation with histamine. Am J Hematol. 1980;8:257-263.
40. Lorant DE, Patel KD, McIntyre TM, McEver RP, Prescott SM, Zimmerman GA. Coexpression of GMP-140 and PAF by endothelium stimulated by histamine or thrombin: a juxtacrine system for adhesion and activation of neutrophils. J Cell Biol. 1991;115:223-234.
41. Koenig A, Norgard-Sumnicht K, Linhardt R, Varki A. Differential interactions of heparin and heparan sulfate glycosaminoglycans with the selectins. Implications for the use of unfractionated and low molecular weight heparins as therapeutic agents. J Clinic Invest. 1998;101:877-889.
42. Csencsits KL, Jutila MA, Pascual DW. Nasal-associated lymphoid tissue: phenotypic and functional evidence for the primary role of peripheral node addressin in naive lymphocyte adhesion to high endothetial venules in a mucosal site. J Immunol. 1999;163:1382-1389.
43. Kunkel EJ, Dunne JL, Ley K. Leukocyte arrest during cytokine-dependent inflammation in vivo. J Immunol. 2000;164:3301-3308.
44. Borges E, Eytner R, Moll T, et al. The P-selectin glycoprotein ligand-1 is important for recruitment of neutrophils into inflamed mouse peritoneum. Blood. 1997;90:1934-1942.
45. Engelberg H. Actions of heparin that may affect the malignant process. Cancer. 1999;85:257-272.
46. Gupta K, Gupta P, Solovey A, Hebbel RP. Mechanism of interaction of thrombospondin with human endothellum and inhibition of sickle erythrocyte adhesion to human endothelial cells by heparin. Biochim Biophys Acta. 1999;1453:63-73.
47. Barabino GA, Liu XD, Ewenstein BM, Kaul DK. Anionic polysaccharides inhibit adhesion of sickle erythrocytes to the vascular endothelium and result in improved hemodynamic behavior. Blood. 1999;93:1422-1429.
48. Hirsh J, Anand SS, Halperin JL, Fuster V. Mechanism of action and pharmacology of unfractionated heparin. Arterioscler Thromb Vasc Biol. 2001;21:1094-1096.
49. Constantinescu AA, Vink H, Spaan JA. Endothelial cell glycocalyx modulates immobilization of leukocytes at the endothelial surface. Arterioscler Thromb Vasc Biol. 2003;23:1541-1547.
50. Stenberg PE, McEver RP, Shuman MA, Jacques YV, Bainton DF. A platelet alpha-granule membrane protein (GMP-140) is expressed on the plasma membrane after activation. J Cell Biol. 1985;101:880-886.
51. McEver RP, Beckstead JH, Moore KL, Marshall-Carlson L, Bainton DF. GMP-140, a platelet alpha-granule membrane protein, is also synthesized by vascular endothelial cells and is localized in Weibel-Palade bodies. J Clin Invest. 1989;84:92-99.
52. Larsen E, Celi A, Gilbert GE, et al. PADGEM protein: a receptor that mediates the interaction of activated platelets with neutrophils and monocytes. Cell. 1989;59:305-312.
53. Padilla A, Moake JL, Bernardo A, et al. P-selectin anchors newly released ultralarge von Willebrand factor multimers to the endothelial cell surface. Blood. 2004;103:2150-2156.
54. Barabino GA, Wise RJ, Woodbury VA, et al. Inhibition of sickle erythrocyte adhesion to immobilized thrombospondin by von Willebrand factor under dynamic flow conditions. Blood. 1997;89: 2560-2567.
55. Frenette PS, Denis CV, Weiss L, et al. P-Selectin glycoprotein ligand 1 (PSGL-1) is expressed on platelets and can mediate platelet-endothelial interactions in vivo. J Exp Med. 2000;191:1413-1422.
56. Geng J-G, Bevilacqua MP, Moore KL, et al. Rapid neutrophil adhesion to activated endothelium mediated by GMP-140. Nature. 1990;343:757-760.
57. Furie B, Furie BC. The molecular basis of platelet and endothelial cell interaction with neutrophils and monocytes: role of P-selectin and the P-selectin ligand, PSGL-1. Thromb Haemost. 1995;74:224-227.
58. Mulligan MS, Warner RL, Lowe JB, et al. In vitro and in vivo selectin-blocking activities of sulfated lipids and sulfated sialyl compounds. Int Immunol. 1998;10:569-575.
59. Romo GM, Dong JF, Schade AJ, et al. The glycoprotein Ib-IX-V complex is a platelet counterreceptor for P-selectin. J Exp Med. 1999;190:803-814.
60. Kaul DK, Tsai HM, Liu XD, Nakada MT, Nagel RL, Coller BS. Monoclonal antibodies to alphaVbeta3 (7E3 and LM609) inhibit sickle red blood cell-endothelium interactions induced by platelet-activating factor. Blood. 2000;95:368-374.
61. Haynes J Jr, Obiako B. Activated polymorphonuclear cells increase sickle red blood cell retention in lung: role of phospholipids. Am J Physiol Heart Circ Physiol. 2002;282:H122-H130.
62. Kaul DK, Liu X, Nagel RL Ameliorating effects of fluorocarbon emulsion on sickle red blood cell-induced obstruction in an ex vivo vasculature. Blood. 2001;98:3128-3131.
63. Sugihara K, Sugihara T, Mohandas N, Mosher D, Hebbel RP. Thrombospondin at pathophysiologic levels mediates adherence of CD36-positive sickle reticulocytes to endothelial cells [abstract]. Blood. 1992;80:334a.
64. Hillery CA, Scott JP, Du MC. The carboxy-terminal cell-binding domain of thrombospondin is essential for sickle red blood cell adhesion. Blood. 1999;94:302-309.
65. Rathjen DA, Ferrante A, Aston R. Differential effects of small tumour necrosis factor-alpha peptides on tumour cell cytotoxicity, neutrophil activation and endothelial cell procoagulant activity. Immunology. 1993;80:293-299.
66. Ulich TR, del Castillo J, Ni RX, Bikhazi N, Calvin L. Mechanisms of tumor necrosis factor alpha-induced lymphopenia, neutropenia, and biphasic neutrophilia: a study of lymphocyte recirculation and hematologic interactions of TNF alpha with endogenous mediators of leukocyte trafficking. J Leukoc Biol. 1989;45:155-167.
67. Taylor PC, Peters AM, Glass DM, Maini RN. Effects of treatment of rheumatoid arthritis patients with an antibody against tumour necrosis factor alpha on reticuloendothelial and intrapulmonary granulocyte traffic. Clin Sci (Lond). 1999;97:85-89.
68. Esmon CT. Possible involvement of cytokines in diffuse intravascular coagulation and thrombosis. Baillieres Best Pract Res Clin Haematol. 1999;12:343-359.
69. Granger DN, Korthuis RJ. Physiologic mechanisms of postischemic tissue injury. Annu Rev Physiol. 1995;57:311-332.
70. Weyrich AS, Buerke M, Albertine KH, Lefer AM. Time course of coronary vascular endothelial adhesion molecule expression during reperfusion of the ischemic feline myocardium. J Leukoc Biol. 1995;57:45-55.
71. Thiagarajan RR, Winn RK, Harlan JM. The role of leukocyte and endothelial adhesion molecules in ischemia-reperfusion injury. Thromb Haemost. 1997;78:310-314.
72. Faller DV. Endothelial cell responses to hypoxic stress. Clin Exp Pharmacol Physiol. 1999;26:74-84.
73. Lowe JB, Ward PA. Therapeutic inhibition of carbohydrate-protein interactions in vivo. J Clin Invest. 1997;99:822-826.
74. Varki A, Varki NM. P-selectin, carcinoma metastasis and heparin: novel mechanistic connections with therapeutic implications. Braz J Med Biol Res. 2001;34:711-717.
75. Hopfner M, Alban S, Schumacher G, Rothe U, Bendas G. Selectin-blocking semisynthetic sulfated polysaccharides as promising anti-inflammatory agents. J Pharm Pharmacol. 2003;55:697-706.
76. Chaplin H Jr, Monroe MC, Malecek AC, Morgan LK, Michael J, Murphy WA. Preliminary trial of minidose heparin prophylaxis for painful sickle cell crises. East Afr Med J. 1989;66:574-584.
77. Wang L, Brown JR, Varki A, Esko JD. Heparin's anti-inflammatory effects require glucosamine 6-O-sulfation and are mediated by blockade of L-and P-selectins. J Clin Invest. 2002;110:127-136.
78. Sundaram M, Qi Y, Shriver Z, et al. Rational design of low-molecular weight heparins with improved in vivo activity. Proc Natl Acad Sci U S A. 2003;100:651-666.